Mecasermin - Teva Pharmaceutical Industries
Alternative Names: CEP 120; IGF-1 - Teva Pharmaceutical Industries; Insulin-like growth factor-1 - Teva Pharmaceutical Industries; KW 6151; Myotrophin; Recombinant human insulin-like growth factor-1; Somatomedin-1 - Teva Pharmaceutical IndustriesLatest Information Update: 25 Sep 2021
At a glance
- Originator Cephalon
- Developer Cephalon; Kyowa Hakko; Merck & Co
- Class Antihyperglycaemics; Growth factors; Peptides
- Mechanism of Action Insulin-like growth factor I stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Amyotrophic lateral sclerosis; Multiple sclerosis; Peripheral nervous system diseases; Renal failure
Most Recent Events
- 18 Sep 2001 Discontinued-III for Amyotrophic lateral sclerosis in Japan (Unknown route)
- 18 Sep 2001 Suspended - Preregistration for Amyotrophic lateral sclerosis in USA (Injection)
- 27 Jul 2001 No-Development-Reported for Peripheral nervous system diseases in USA (Unknown route)